Introduction
The MEK/ERK/MAP kinase signal transduction pathway is known to regulate cellular proliferation, survival and differentiation. With respect to cell growth, the MEK/ERK/MAP kinase pathway acts to transduce proliferative signals from cell surface receptors to the nucleus, thereby promoting cell cycle progression. The biochemical events triggered by activation of cell surface receptor tyrosine kinases include the sequential activation of the Raf and MEK kinases. Two distinct MEK enzymes, MEK-1 and MEK-2, have been identified. 1 The highly specific MEK-1 and MEK-2 phosphorylate and activate the 44 kDa and 42 kDa MAP kinases, ERK-1/MAPK and ERK-2/MAPK, respectively. [2] [3] [4] [5] [6] [7] Once activated, ERK/MAP kinases activate other kinases, including p90 RSK , and transcription fac-tors such as Elk-1, STATs, Myc, and AP-1. [8] [9] [10] [11] [12] A role for ERK/MAP kinases in oncogenesis has been suggested from studies using mutant versions of the MEK proteins. Expression of a constitutively active MEK mutant was found to promote transformation of rodent fibroblasts, 13 while a dominantnegative MEK mutant reversed transformation in NIH3T3 cells overexpressing the ras and src oncogenes. 14 The MEK/ERK/MAP kinase pathway also has an important role in modulating the survival of hematopoietic cells. Studies using the myeloid precursor cell lines, TF-1 and FDCP-1, found that MEK-1 activation abrogated the cytokine dependence of a subset of these cells. 15 Another study demonstrated the importance of the Raf/MEK/MAP kinase cascade in the conversion of a subset of FL5.12 cells to a cytokineindependent phenotype. 16 In addition, Perkins et al 17 have shown that expression of activated MEK-1 in BAF/3 cells, while failing to promote cytokine-independent proliferation, did result in suppression of apoptosis. There have also been numerous reports suggesting interactions between the Raf/MEK/MAP kinase pathway and apoptosis regulatory proteins. [18] [19] [20] [21] [22] [23] [24] [25] Emerging evidence implicates the MEK/ERK/MAP kinase pathway in the differentiation of certain cell types. The induction of neuronal differentiation in rat PC12 cells requires sustained activation of ERK/MAP kinases, 26, 27 as does the maturation of thymocytes from CD4 −
CD8
− to CD4 + CD8 + cells. 28 The ERK/MAP kinase pathway is also required for the development of the visual cortex. 29 However, other types of cellular differentiation, including myogenesis and adipogenesis, appear to proceed in a MAPK-independent manner. 30 In the case of hematopoietic cell differentiation, antisense oligonucleotides and dominant-negative mutants targeting MEK-1 have been shown to inhibit macrophage-like differentiation of TF-1a cells. 31 Moreover, activation of ERK/MAP kinases was shown to be important for megakaryocytic differentiation of K562 cells. 32, 33 While these observations indicate an involvement of MEK/ERK/MAP kinases in hematopoietic differentiation, the detailed role of the MEK/ERK/MAP kinase pathway in myeloid differentiation, as well as differentiationinduced apoptosis remains poorly understood.
In this study, we employed a highly specific pharmacologic inhibitor of MEK-1 and MEK-2, U0126, 34 to investigate the importance of the MEK/ERK/MAP kinase pathway in the differentiation and apoptosis of established myeloid cell lines. In particular, our studies focused on HL-60 acute myeloid leukemic cells. HL-60 cells represent a convenient model to study biochemical factors regulating myeloid differentiation, as these cells can be induced to differentiate along either monocytic or granulocytic lineages. Treatment of HL-60 cells with dimethyl sulfoxide (DMSO) or retinoic acid (RA) leads to granulocytic differentiation, while monocytic differentiation can be induced by agents such as phorbol 12-myristate 13-acetate (PMA), 1,25-dihydroxy vitamin D3, or sodium butyrate. [35] [36] [37] The induction of myeloid differentiation in HL-60 cells is also associated with apoptotic cell death, reminiscent of what is seen during myeloid differentiation in vivo. 38, 39 Previous studies have shown that treatment of HL-60 cells with RA leads to activation of ERK-2, and PMA treatment leads to activation of both ERK-1 and ERK-2. [40] [41] [42] In this report, we demonstrate a requirement for the MEK/ERK/MAP kinase pathway in both monocytic and granulocytic differentiation.
Materials and methods

Chemicals and antibodies
Phorbol 12-myristate 13-acetate (PMA) and retinoic acid (RA) were obtained from Sigma Chemical (St Louis, MO, USA), and U0126 from Cell Signaling Technology (Beverly, MA, USA). PMA and U0126 were dissolved in dimethyl sulfoxide (DMSO) and RA in ethanol, and stock solutions were stored at −20°C.
Activation of MEK-1 and MEK-2 was detected using an antiphospho-MEK-1/-2 polyclonal antibody obtained from Cell Signaling Technology. The antibody detects activated forms of MEK-1/-2 that have been phosphorylated on two conserved serine residues (corresponding to serines 217 and 221 in human MEK-1). The levels of total MEK-1/-2 protein were determined using an anti-MEK-1/-2 polyclonal antibody also obtained from Cell Signaling Technology. Activation of ERK-1 and -2 was detected using anti-phospho-ERK-1/-2 polyclonal antibody from Cell Signaling Technology. The antibody detects activated forms of p44 ERK-1 and p42 ERK-2 that have been phosphorylated on conserved threonine and tyrosine residues, corresponding to residues 202 and 204 in ERK-1 and found in the sequence motif T*EY*. Total ERK protein levels were determined using an anti-ERK-1/-2 polyclonal antibody from Cell Signaling Technology. Probing with anti-␤-actin monoclonal antibody (Sigma) was used to demonstrate equal protein loading.
Phycoerythrin-labeled anti-CD11b antibody (CD11b-PE), fluorescein isothiocyanate-labeled anti-CD14 antibody (CD14-FITC) and the APO-BRDU DNA fragmentation kit were obtained from BD Pharmingen (San Diego, CA, USA). The expression of p21 WAF1/Cip1 was detected using horseradish peroxidase (HRP)-conjugated goat polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA). HRP-conjugated secondary antibodies for Western blotting were obtained from Promega (Madison, WI, USA).
Cell culture and induction of differentiation
HL-60 and U937 cells were obtained from the American Type Culture Collection (ATCC) (Richmond, MD, USA) and cultured in RPMI 1640 medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco/BRL). To induce differentiation of HL-60, cells in logarithmic growth were seeded at 3 × 10 5 /ml and treated with 20 ng/ml PMA dissolved in dimethyl sulfoxide (DMSO; final concentration of DMSO in culture medium was 0.1%) or 5 m retinoic acid dissolved in ethanol. Control cultures were treated similarly with DMSO or ethanol. To induce differentiation of U937, cells in logarithmic growth were seeded at 3 × 10 5 /ml and treated with 20 ng/ml PMA dissolved in dimethyl sulfoxide (final concentration of DMSO in culture medium was 0.1%).
The murine myeloid progenitor cell line 32D cl.3 was maintained in RPMI 1640 medium supplemented with 10% heatinactivated fetal bovine serum and 10% WEHI-conditioned media (WCM) as a source of IL-3. To induce granulocytic differentiation, cells were seeded at 2 × 10 5 /ml in RPMI/20% FBS/1% WCM and treated with 30 ng/ml of recombinant G-CSF (Peprotech, Rocky Hill, NJ, USA).
To test the role of ERK/MAP kinase activation in differentiation, HL-60, U937, or 32D cl.3 cells were pre-incubated for 2 h with 5 m of the MEK-1/-2 inhibitor U0126. To determine a dose-response to U0126, HL-60 cells were pretreated as described with varying doses of U0126, followed by PMA treatment for 1 h and immunoblot analysis of ERK-1/-2 activation.
Immunoblotting
For preparation of cell extracts, cells were washed with cold phosphate-buffered saline (PBS) and lysed in lysis buffer (20 mm Hepes pH 7.5, 150 mm NaCl, 1 mm EGTA, 1.5 mm MgCl 2 , 10% glycerol, 1% Triton X-100, 1 mm PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin, 50 mm NaF, 2 mm sodium orthovanadate and 10 mm sodium pyrophosphate) for 30 min on ice. The lysates were clarified by centrifugation at 14 000 r.p.m. for 10 min and the supernatants were stored at −80°C.
For immunoblot analyses, equal quantities of protein (30-50 g/lane) from the HL-60 cell extracts were separated by SDS/PAGE electrophoresis and transferred to nitrocellulose. Membranes were blocked for 1 h in TBS (10 mm Tris pH 8.0, 50 mm NaCl) containing 0.1% Tween-20 (TBS-T) and 5% low fat milk. Filters were then incubated with primary antibodies overnight at 4°C, followed by four washes at room temperature in TBS-T. The filters were then incubated with conjugated secondary antibodies for 1 h at room temperature. Following an additional four washes in TBS-T, immunoreactive proteins were detected using an enhanced chemiluminescence detection system according to the manufacturer's instructions (NEN, Boston, MA, USA).
Assessment of differentiation
Granulocytic differentiation was determined by nitroblue tetrazolium (NBT) reduction and monocytic differentiation was assessed using non-specific esterase (NSE) staining after 72 h of treatment. 43, 44 For each datapoint, a total of 200 cells was counted from five different fields. Percent differentiation was calculated as the number of cells that were positive for the respective enzyme divided by the total number of cells counted.
For morphological assessment of differentiation, 100 l of cell suspension from untreated and PMA, RA or G-CSF-treated cultures were cytospun on to slides and stained with Hema 3 stain set (Fisher Scientific, Pittsburgh, PA, USA). For each datapoint, a total of 500 cells was scored for morphological features of differentiation from five different fields. Percent differentiation was calculated as the number of cells that were differentiated divided by the total number of cells counted.
Surface receptor expression of CD11b or CD14
HL-60 cells (5 × 10 5 ) treated with either PMA or RA, with or without U0126, were incubated with 50 l of PE-labeled anti-CD11b or FITC-labeled anti-CD14 monoclonal antibody for 30 min at 4°C. For every sample, separate aliquots of cells were also incubated with isotype antibody controls (BD Pharmingen) to determine non-specific staining. Following incubation with antibodies, cells were washed twice in flow wash buffer (PBS containing 1% FBS and 0.1% azide) and analyzed by flow cytometry on an Epics Coulter XL equipped with a 488 nm argon laser. For each sample, a total of 10 000 cells was analyzed. U937 cells treated with PMA were similarly labeled and analyzed for CD11b and CD14 surface marker expression.
Cell viability
The viabilities of suspension cultures of untreated or RAtreated cells were determined using trypan blue. In the case of adherent cells (PMA treatment), cells were detached from the plate using 0.25% Trypsin/EDTA (Gibco/BRL) and cell scraping. The detached cells were combined with the floating cells, and the cells were washed twice in PBS before determining viabilities by trypan blue exclusion. For each datapoint, a total of 100 cells was counted in triplicate and viabilities were presented as the mean ± standard deviation.
Assessment of apoptosis
Apoptosis was assessed by flow cytometric analysis of a TUNEL labeling procedure. Briefly, HL-60 cells (1-2 × 10 6 ) from untreated and treated cultures were washed twice with cold PBS and resuspended in 0.5 ml of PBS. The cell suspension was added to 5 ml of 1% paraformaldehyde in PBS and kept on ice for 15 min. The cells were then washed twice with PBS and resuspended in 0.5 ml of PBS. The cell suspension was added to 5 ml of ice-cold 70% ethanol and stored at −20°. For labeling of the DNA, cells were pelleted by centrifugation and washed twice with wash buffer. Cells were then incubated with DNA labeling solution (reaction buffer, TdT enzyme, Br-dUTP) (BD Pharmingen) for 60 min at 37°C. After two washes with rinse buffer, the cell pellet was resuspended in 0.1 ml of the anti-BrDU antibody (BD Pharmingen) and incubated in the dark for 30 min at room temperature. PI/RNase A solution (0.5 ml) was added and incubated for a further 30 min before analysis on an Epics Coulter XL flow cytometer. A minimum of 20 000 events was collected and analyzed for each sample.
Results
Activation of the MEK/ERK/MAP kinase signaling pathway during monocytic and granulocytic differentiation
Treatment of HL-60 cells with PMA or RA induces functional and morphological features that are characteristic of differentiated macrophages or granulocytes. To understand the early events that lead to PMA-induced monocytic differentiation and RA-induced granulocytic differentiation in HL-60 cells, we studied the activation of the MEK/ERK/MAPK pathway by analyzing the phosphorylation status of these molecules using phospho-specific antibodies. Activation of MEK-1/-2 is coincident with serine phosphorylation (residues 217/221 in MEK-1) by the upstream kinases, MEKK or Raf-1. Time-course Leukemia analysis of MEK phosphorylation revealed that PMA induced rapid serine phosphorylation/activation of MEK-1/-2 within 5 min of treatment (Figure 1a ). These levels of phosphorylation were sustained even after 24 h. By contrast, immunoblotting with an antibody that detects total MEK-1/-2 protein revealed that PMA treatment did not affect the cellular levels of these enzymes (Figure 1b) . Activation of MEK-1/-2 within 5 min was also detected on RA treatment, with phosphorylation levels peaking at 30 min and decreasing to background levels by 24 h (Figure 1d ). As with PMA treatment, RA did not alter the total levels of MEK-1/-2 ( Figure 1e) .
The activation of ERKs also occurs through phosphorylation. In this case, MEK-1 and -2 phosphorylate ERKs at threonine and tyrosine residues in the sequence T*EY* (thr202 and tyr204 in ERK-1). The phospho-ERK polyclonal antibody we employed detects this phosphorylated sequence in the ERK proteins, enabling detection of the activated enzymes. Timecourse analysis of phosphorylated ERKs revealed that PMA induced rapid activation of ERK-1 and -2 within 5 min of treatment (Figure 2a) . The levels of phospho-ERK-1 and -2 declined somewhat thereafter but continued to show sustained activation even after 24 h. Rapid ERK activation (within 5 min) was also detected following RA treatment (Figure 2d ). However, in contrast to PMA treatment, RA induced primarily ERK-2 activation during early time-points (Figure 2d ). The activation of ERK-2 by RA was sustained even to 24 h. Subsequent experiments revealed that RA treatment resulted in a greatly delayed, but not early, activation of the ERK-1 enzyme. Simi- lar results have been reported by Yen et al. 40 Immunoblotting with an antibody that detects total ERK-1/-2 protein demonstrated no change in the cellular levels of these enzymes upon PMA or RA treatment (Figure 2b and e) .
Inhibition of the MEK/ERK/MAP kinase signaling pathway by U0126
To determine whether PMA-or RA-induced activation of ERK-1 and -2 was due to the activity of MEK, we used a specific MEK inhibitor, U0126. The U0126 inhibitor potently inhibits both MEK-1 and MEK-2 enzymes. 34 HL-60 cells were preincubated with varying doses of U0126 (0-50 m) for 2 h before adding PMA (20 ng/ml) for 1 h. As shown in Figure 3a , there was a dose-dependent inhibition of ERK-1 and ERK-2 phosphorylation indicating that this activation is MEK-depen-
Figure 3
Inhibition of ERK activation by U0126. HL-60 cells were pre-treated with varying doses of U0126 for 2 h followed by PMA treatment for 1 h. Lysates were prepared and proteins (40 g/lane) were electrophoresed on a 12.5% SDS/PAGE gel, then transferred to nitrocellulose membranes. Filters were probed with anti-phospho-ERK-1/-2 (a) and anti-total ERK (b) polyclonal antibodies. To demonstrate equal protein loading, the anti-phospho-ERK filter was stripped and reprobed with anti-␤-actin antibody (c). dent. By contrast, treatment with U0126 did not significantly alter the levels of total ERK-1/-2 proteins (Figure 3b) . Similar results were seen in the case of RA-induced ERK activation (data not shown).
At a dose of 5 m, no effect of U0126 on cell viability was observed over a 72 h time-frame. However, at higher doses, U0126 treatment resulted in a significant, rapid loss of viability (data not shown). In view of these findings, U0126 was used at a dose of 5 m in subsequent experiments. Figure 4a and b depict the effect of 5 m U0126 on PMA-and RA-induced ERK-1/-2 phosphorylation, respectively, after 3 days of treatment. A substantial reduction in ERK-1 and ERK-2 phosphorylation on pretreatment with U0126 was observed in PMA-treated cells, and a complete inhibition of ERK activation was seen in RA-treated cells.
MEK/ERK/MAP kinase signaling is essential for monocytic and granulocytic differentiation of HL-60 cells
To determine whether the MEK/ERK pathway plays a role in the processes of PMA-and RA-induced differentiation, HL-60 cells were treated with U0126 at a dose of 5 m prior to induction of differentiation. Analysis of differentiation using cytochemical markers such as non-specific esterase (NSE) for monocytic/macrophage differentiation revealed a marked reduction in monocytic differentiation when HL-60 cells were pre-treated with U0126 (Figure 5a ). Morphological assessment of Hema 3-stained cytospin preparations also revealed a significant inhibition of monocytic differentiation by U0126 (Figure 5b ). Similar inhibition by U0126 was detected when differentiation was assessed by flow cytometric analysis of CD11b expression, a marker of myeloid differentiation (Figure 5c ). CD11b expression after 72 h was reduced from 96.7% in PMA-treated cultures to 29.9% in PMA + U0126 cultures. Analysis for expression of the monocytic marker CD14 further confirmed the marked inhibition of monocytic differentiation by U0126 (Figure 5c ).
U0126 also potently inhibited RA-induced granulocytic differentiation, as assessed by NBT reduction assay (Figure 6a The effect of U0126 on PMA-(a) and RA-induced (b) ERK activation after 3 days of treatment. HL-60 cells were pre-treated with U0126 (5 m) for 2 h followed by PMA (20 ng/ml) or RA (5 m) treatment for 72 h. Lysates were prepared on day 3 and proteins (40 g/lane) were electrophoresed on a 12.5% SDS/PAGE gel and transferred to nitrocellulose membranes. Filters were probed with antiphospho-ERK-1/-2 polyclonal antibody.
for CD11b was reduced from 42.5% to 12.3% upon U0126 pre-treatment.
The cell cycle inhibitor p21 WAF1/Cip1 has been reported to be upregulated during PMA-induced monocytic differentiation. 45, 46 To confirm the inhibitory effect of U0126 on differentiation, we studied the expression of p21 WAF1/Cip1 in HL-60 cells treated with PMA alone, or in combination with U0126. As shown in Figure 7 , p21 WAF1/Cip1 was dramatically upregulated in the PMA-treated HL-60 cells. However, upregulation of p21 WAF1/Cip1 was potently inhibited by
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Figure 5
The MEK-1/-2 inhibitor potently inhibits PMA-induced monocytic differentiation of HL-60 cells. Cells were pre-treated with U0126 (5 m) for 2 h, followed by treatment with PMA for 72 h. pre-treatment with U0126, confirming the impact of this inhibitor on differentiation.
MEK/ERK/MAP kinase signaling is essential for monocytic differentiation of U937 cells and granulocytic differentiation of 32D cells
To determine whether signaling by the MEK/ERK/MAP kinase pathway is also required for myeloid differentiation in other cell lines, we examined the impact of U0126 on PMAinduced monocytic differentiation of U937 cells and on G-CSF-induced granulocytic differentiation of 32D cells. U937 cells were treated with U0126 at a dose of 5 m prior to the addition of 20 ng/ml PMA. Both NSE staining as well as morphologic analysis indicated a dramatic reduction in monocytic differentiation when U937 cells were pre-treated with U0126 (Figure 8a and b) . Flow cytometric analyses of CD11b and CD14 differentiation markers also confirmed the impact of U0126 on monocytic differentiation, with CD11b expression being reduced from 56.7% in PMA-treated cultures to 1.7% in PMA + U0126 cultures on day 3 (Figure 8c) . A similar inhibition of CD14 expression by U0126 was observed (Figure 8c ). U0126 also impacted granulocytic differentiation of 32D cells treated with G-CSF. The percent of G-CSFinduced granulocytic differentiation seen on day 9 was reduced from 64.9% to 22.1% when 32D cells were pretreated with 5 m U0126 (data not shown). Taken together, these results demonstrate that signaling via the MEK/ERK/MAP kinase pathway is required for myeloid differentiation in each of the three cell lines examined. Furthermore, inhibition of this pathway abrogates differentiation resulting from both chemical and cytokine inducers of myeloid differentiation.
Impact of U0126 on differentiation-induced apoptosis
The differentiation of hematopoietic cells is often coupled to the activation of apoptosis. In vivo, cells undergoing granulocytic differentiation manifest rapid activation of apoptosis, and are therefore short-lived. Cells in the monocytic lineage are somewhat longer lived, but still succumb to cell death. 47 These observations have been replicated in the HL-60 model system. 47, 48 Therefore, we investigated the impact of U0126 on differentiation-induced HL-60 cell death using trypan blue exclusion. As shown in Figure 9a , cell viability was reduced to 17% following treatment for 5 days with PMA alone. By contrast, the viability of cells treated for 5 days with both PMA
Figure 6
The MEK-1/-2 inhibitor potently inhibits RA-induced granulocytic differentiation of HL-60 cells. Cells were pre-treated with U0126 (5 m) for 2 h, followed by treatment with RA for 72 h. (a) Cells were evaluated for differentiation based on NBT staining. For each sample, a total of 200 cells was counted from five different fields. (b) Granulocytic differentiation was evaluated by morphological examination of Hema 3-stained cytospin preparations. Differentiation was scored from five fields containing a total of 500 cells on the basis of neutrophilic features. The percent of cells exhibiting granulocytic morphology under each condition is shown. (c) Flow cytometric analysis of CD11b expression was used to assess differentiation as described for Figure 5c .
Figure 7
U0126 abrogates p21WAF1/Cip1 upregulation in PMAtreated cells. HL-60 cells were pre-treated with U0126 (5 m) for 2 h, followed by treatment with PMA (20 ng/ml). Cells were harvested after 24 h and proteins (20 g/lane) were electrophoresed on a 15% SDS/PAGE gel and transferred to a nitrocellulose membrane. The filter was probed with anti-p21 WAF1/Cip1-HRP conjugated antibody. The filter was subsequently stripped and reprobed with anti-␤-actin antibody to verify equal protein loading. and U0126 was 80%. Similar results were obtained when apoptosis was examined by the DNA fragmentation or terminal deoxynucleotidyltransferase dUTP nick end labeling (TUNEL) assay (Figure 9b ). Apoptosis was reduced from 58.0% in cultures treated with PMA alone to 10.6% in cultures treated with PMA + U0126. Thus, U0126 potently inhibited both PMA-induced differentiation (Figure 5a-c) , as well as PMA-induced loss of cell viability.
The impact of U0126 on the viability of RA-treated HL-60 cells, however, was different from what we observed in PMAtreated cells. While cells treated with RA alone showed an 86.5% loss in viability at day 5, the inclusion of 5 m U0126 in these experiments did not significantly change this loss in viability (Figure 9c ). Examination of RA-induced apoptosis by TUNEL assay yielded similar results, with no apparent impact of U0126 on cell death (data not shown). However, a partial inhibition of RA-induced apoptosis was seen when lower doses of U0126 were used. In the presence of 1.0 m U0126, RA-induced apoptosis was reduced by 42%, and in the presence of 2.5 m U0126, apoptosis was reduced by as much as 49% (data not shown). No inhibition of apoptosis was seen at U0126 doses lower than 1.0 m or higher than 5 m. In summary, while some inhibition of RA-induced apoptosis was detected at 1.0 and 2.5 m U0126, these levels of inhibition did not equal the nearly complete inhibition by U0126 of PMA-induced apoptosis. This suggests that there are differences in the pathways that lead to PMA-and RA-induced HL-60 cell apoptosis.
Figure 8
The MEK-1/-2 inhibitor potently inhibits PMA-induced monocytic differentiation of U937 cells. (a) NSE staining was used as a measure of differentiation. For each sample, a total of 200 cells was counted from five different fields. (b) Monocytic/macrophage differentiation was determined by morphological examination of Hemastained cytospin preparations as in Figure 5 . (c) Flow cytometric analyses of CD11b and CD14 expression on U937 cells were used to assess differentiation as described for HL-60 cells in Figure 5c .
Discussion
ERK/MAP kinases are involved in diverse processes such as proliferation, differentiation and the suppression of apoptosis. While there are many documented reports on the role of the MEK/ERK/MAP kinase pathway in cell growth and transformation, [49] [50] [51] [52] there are few reports on the role of these kinases in differentiation, particularly myeloid differentiation.
Previous studies have established a role for protein kinase C (PKC) signaling in myeloid differentiation. 56 An additional report has indicated that PMA-induced MAPK activation is dependent on PKC signaling. 42 The aim of this study was to evaluate the importance of the MEK/ERK/MAP kinase pathway in myeloid differentiation. We have shown that differentiation inducers like PMA and RA activate MEK-1/-2 as well as ERK-1/-2 early in the differentiation process. To determine the importance of this activation, a potent and specific inhibitor, U0126, of the upstream kinases MEK-1 and -2 was employed. Pre-incubation with U0126 inhibited PMA-and RA-induced ERK-1/-2 activation in a dose-dependent manner. Importantly, U0126 also exhibited a potent inhibitory effect on both monocytic and granulocytic differentiation. Approximately 70% inhibition of monocytic differentiation was observed on day 3 when cells were pre-treated with U0126, and this inhibition correlated with the inhibition of ERK phosphorylation. The impact of U0126 on RA-induced differentiation was similar, with granulo cytic differentiation being reduced from 42.5% to 12.3% on day 3.
Our data clearly demonstrate the involvement of the MEK/ERK/MAP kinase pathway in PMA-, RA-and G-CSFinduced myeloid differentiation. The role of these kinases in hematopoietic differentiation is an area of increasing interest. Sustained activation of the ERK/MAP kinase pathway has been shown to be required for the megakaryocytic differentiation of K562 cells. 33, 57 Another study showed the involvement of ERKs in both the growth and the erythroid-like differentiation of K562 cells. 58 In another report, PMA was shown to induce expression of the cell cycle regulatory proteins p21 WAF1 and p27
Kip1 in a MAPK-dependent manner. 46 Our study documents a requirement for ERK activation in both monocytic and granulocytic differentiation. By contrast, a previous report 56 has shown that the p42/p44 ERK/MAP kinase cascade is activated by PMA in HL-60 cells but is not essential for macrophage-like differentiation. However, this study employed a different MEK inhibitor, PD098059, which is a more potent inhibitor of MEK-1 than MEK-2.
While U0126 was found to potently inhibit both monocytic and granulocytic differentiation, we did observe an intriguing difference in the ability of this compound to inhibit PMA-vs RA-induced cell death. Apoptosis resulting from PMA treatment was completely abrogated by U0126 pretreatment. In contrast, U0126, while inhibiting RA-induced differentiation, only partially inhibited RA-induced cell death. These results indicate that there are differences in the pathways of cell death in PMA-and RA-treated cells. Whether there are clear differences in the cell death pathways induced by monocytic vs granulocytic differentiation remains to be determined. Further studies on the involvement of MEK/ERK/MAP kinase signaling in the regulation of pro-and anti-apoptotic molecules should improve our understanding of the role played by these kinases in differentiation-induced apoptosis.
In summary, our results clearly establish an important role for the MEK/ERK/MAP kinase pathway in monocytic as well as granulocytic differentiation of myeloid cell lines. Future studies examining the impact of U0126 on cytokine-induced differentiation of primary, bone marrow-derived cells will help to establish the physiological significance of MEK signaling during normal myeloid differentiation. Studies involving expression of dominant-negative MEKs should also help to confirm the requirement for MEK signaling. Finally, expression of constitutively active MEKs will make it possible to determine whether robust signaling via the MEK/ERK/MAP kinase pathway is sufficient to induce myeloid differentiation. 
